Srinivas Akkaraju - 13 Mar 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Director
Signature: /s/ Srinivas Akkaraju
Issuer symbol: MLYS
Transactions as of: 13 Mar 2025
Net transactions value: +$8,100,000
Form type: 4
Filing time: 17 Mar 2025, 21:04:15 UTC
Previous filing: 24 Feb 2025
Next filing: 18 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Purchase	$8,100,000	+600,000	+12%	$13.50	5,674,916	13 Mar 2025	By Samsara BioCapital, L.P.	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities are directly held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

Content

Securities are directly held by Samsara BioCapital L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.